Our previous research found that cyclin G2 plays an anti-tumor role in a variety of cancer cells, and overexpression of cyclin G2 in glioma combined with PD-1 therapy can reverse the immunosuppressive tumor microenvironment. This evidence concerns the gene CCNG2 and central nervous system cancer.